- Home
- LPCN vs LGVN Comparison
LPCN vs LGVN Comparison
Compare LPCN & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- LGVN
- Stock Information
- Founded
- LPCN 1997
- LGVN 2014
- Country
- LPCN United States
- LGVN United States
- Employees
- LPCN N/A
- LGVN N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- LPCN Health Care
- LGVN Health Care
- Exchange
- LPCN Nasdaq
- LGVN Nasdaq
- Market Cap
- LPCN 27.1M
- LGVN 25.2M
- IPO Year
- LPCN N/A
- LGVN 2021
- Fundamental
- Price
- LPCN $4.62
- LGVN $1.81
- Analyst Decision
- LPCN Strong Buy
- LGVN Strong Buy
- Analyst Count
- LPCN 1
- LGVN 3
- Target Price
- LPCN $10.00
- LGVN $8.67
- AVG Volume (30 Days)
- LPCN 32.3K
- LGVN 295.3K
- Earning Date
- LPCN 03-06-2025
- LGVN 02-25-2025
- Dividend Yield
- LPCN N/A
- LGVN N/A
- EPS Growth
- LPCN N/A
- LGVN N/A
- EPS
- LPCN N/A
- LGVN N/A
- Revenue
- LPCN $7,922,926.00
- LGVN $1,852,000.00
- Revenue This Year
- LPCN N/A
- LGVN $208.32
- Revenue Next Year
- LPCN N/A
- LGVN $43.96
- P/E Ratio
- LPCN N/A
- LGVN N/A
- Revenue Growth
- LPCN N/A
- LGVN 141.46
- 52 Week Low
- LPCN $3.20
- LGVN $0.77
- 52 Week High
- LPCN $11.79
- LGVN $9.00
- Technical
- Relative Strength Index (RSI)
- LPCN 43.02
- LGVN 48.61
- Support Level
- LPCN $4.25
- LGVN $1.65
- Resistance Level
- LPCN $4.73
- LGVN $1.89
- Average True Range (ATR)
- LPCN 0.33
- LGVN 0.13
- MACD
- LPCN -0.04
- LGVN 0.00
- Stochastic Oscillator
- LPCN 20.80
- LGVN 25.42
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.